|
Early Risk Predictors For Chronic Pulmonary Disease Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Early Risk Predictors For Chronic Pulmonary Disease conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Early Risk Predictors For Chronic Pulmonary Disease Clinical research trials and Early Risk Predictors For Chronic Pulmonary Disease healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Early Risk Predictors For Chronic Pulmonary Disease. Early Risk Predictors For Chronic Pulmonary Disease Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Early Risk Predictors For Chronic Pulmonary Disease clinical trial. Participants typically obtain the most effective healthcare available for their Early Risk Predictors For Chronic Pulmonary Disease condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Early Risk Predictors For Chronic Pulmonary Disease  Early Risk Predictors For Chronic Pulmonary Disease
Early Risk Predictors For Chronic Pulmonary Disease
For Condition: Chronic Obstructive Pulmonary Disease,Asthma,Lung Diseases, Obstructive
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To continue to evaluate risk factors heretofore determined to be important predictors of chronic respiratory symptoms, diagnosis of asthma, and alterations in expected levels of lung function in children and adolescents in a new population of young adult women.
Details: BACKGROUND: This longitudinal study was initiated in 1975 when a stratified random sample of children, ages 5-9 years and living in the East Boston area of the City of Boston, was selected. Annual lung function tests were performed on the children and their families and questionnaires administered on respiratory illness history, smoking history, disability from cardiac disease, age of menarche in female children and demographic data such as type of heating, type of fuel for cooking, types of air purifying devices, and area of residence. A subset of the cohort had repeated measures of eucapneic hyperventilation with cold air. The cohort was also studied with helium-oxygen protocol. Analysis focused on validation of existing models, including the autoregressive model, for lung growth in children and adolescents and the decline in growth in adults. DESIGN NARRATIVE: The longitudinal study was renewed in 1995. The overall aim of this continuing investigation was to evaluate risk factors heretofore determined to be important predictors of chronic respiratory symptoms, diagnosis of asthma, and alterations in expected levels of lung function in children and adolescents in a new population of young adult women. Within the existing population the investigators had already obtained repeated observations of airways responsiveness and measures of morbidity on a group of young adults aged up to 35. These data, however, were limited in total numbers to a few hundred. They expanded the observations to 883 women aged 17-22 specifically to assess risk factors that affected maximum attained level of lung function. Data on the entire cohort were collected cross-sectionally and included standardized questionnaires on respiratory symptoms, diseases, and exposures. Pulmonary function, height, and immediate medication history were subsequently obtained on the entire cohort, along with blood specimens that were analyzed immediately for WBC and total eosinophil counts and stored for subsequent analysis of lgE and cytokine profiles. To assess the impact of a history of asthma (wheeze), all subjects reporting asthma with the use of medication in the last month, a one-third sample of women with symptoms with no medication use, and an equal number of asymptomatic age and smoking matched women had spirometry repeated before and after bronchodilator use. The results of these investigations provided insights into risk factors affecting maximum obtained level of pulmonary function in women. Since level of function is a critical determinant of risk of developing chronic obstructive lung disease, the determination of the interaction of factors other than cigarette smoking led to better strategies for helping women to stop smoking, which would be a major step in reducing morbidity and mortality from chronic respiratory disease. The study was formerly supported by R01HL22528.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 2002;
Study Start Date: September 1977
Record last reviewed: April 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005281
Other Chronic Obstructive Pulmonary Disease Studies:
1. Lay-Led Smoking Cessation Approach for Southeast Asian Men
2. A study using an investigational new medicine looking at its effects on pulmonary function and respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD)
3. To evaluate the long-term safety of (R,R)-formoterol in subjects with COPD
4. Diet and Chronic Obstructive Pulmonary Disease
5. Chronic Obstructive Pulmonary Disease Gene Localization
Related Studies:
Other Chronic Obstructive Pulmonary Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Early Risk Predictors For Chronic Pulmonary Disease
|
|
|
|
|
|
|
|
